ABSTRACT

Aim:

To review the evolution and use of prostate specific antigen (PSA) in clincal aplications in a brief report with historical perspective.

Results:

For more than a decade PSA is used as a reliable biomarker for screning and post-treatment follow up of prostate cancer. The PSA thresholds are continually refined and altered in years. The use of PSA isoforms and PSA kinetics increased the strength of PSA in diagnosis and follow-up of cancer.

Conclusion:

PSA is a reliable biomaker for follow-up after prostate cancer. Its diagnostic strength needs to be supported with several other parameters. The search for new biological markers that can complement PSA still continues.